학술논문
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”: [ESMO Open 3 (2018) e000375]
Document Type
Erratum
Author
Source
In ESMO Open April 2023 8(2)
Subject
Language
ISSN
2059-7029